Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cash-Rich Ipsen Opens Up Checkbook For 2019

Executive Summary

2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.

You may also be interested in...



Pfizer Well-Placed To Lead First-Line Advanced RCC Market

Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded. 

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel